Cadila sells two of its brands as Glenmark bags USFDA nod for generic antibiotic cream

INDIA – Cadila Healthcare has announced that its subsidiary has inked a pact with Integrace Private Limited to sell two brands, Mifegest and Cytolog at an undisclosed amount.

Zydus Healthcare Ltd, a wholly-owned subsidiary of the company, has inked the agreement with Integrace, a part of the portfolio companies of private equity firm True North.

The said transaction is expected to be completed within 30 days from the date of execution of agreement, subject to customary approvals,” Cadila Healthcare said in a regulatory filing.

Meanwhile, Cadila’s competitors Glenmark Pharmaceuticals has announced that it has received final approval from the United States Food & Drug Administration for clindamycin phosphate foam.

Clindamycin phosphate foam is the generic version of evoclin foam of Mylan Pharmaceuticals Inc.

According to IQVIA sales data for the 12-month period ending July 2021, the Evoclin Foam market achieved annual sales of approximately US$12.0 million. Clindamycin is used to treat severe acne in adults and children who are at least 12 years old.

Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” the company said in its recent release.

Glenmark had earlier received tentative approval from the USFDA for Nintedanib Capsules, 100mg and 150mg.

Nintedanib is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

According to IQVIA sales data for the 12-month period ending April 2021, the Capsules, 100 mg and 150 mg market achieved annual sales of approximately US$$1.6 billion, which speaks to the huge market opportunities Glenmark is hoping onto.

The pharmaceutical giant is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology.

Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.